Volatility and Risk
Windtree Therapeutics’ stock is 45% less volatile than the S&P 500, with a beta of 0.55. In contrast, INmune Bio’s stock is 85% more volatile, with a beta of 1.85.
Profitability
Here’s how Windtree Therapeutics and INmune Bio compare in terms of net margins, return on equity, and return on assets:
| Net Margins | Return on Equity | Return on Assets | |
| Windtree Therapeutics | N/A | -347.82% | -81.41% |
| INmune Bio | -26,333.59% | -103.56% | -68.94% |
Earnings & Valuation
Comparing revenues, earnings, and valuation metrics:
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Windtree Therapeutics | N/A | N/A | -$20.29 million | ($36.29) | -0.03 |
| INmune Bio | $85,000.00 | 1,189.25 | -$30.01 million | ($1.92) | -2.66 |
Windtree has higher earnings but lower revenue than INmune Bio. INmune Bio is priced more affordably based on the price-to-earnings ratio.
Analyst Recommendations
Current ratings and target prices indicate:
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Windtree Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
| INmune Bio | 0 | 0 | 2 | 0 | 3.00 |
INmune Bio has a target price of $20.00, indicating a potential increase of 291.39%. Analysts favor INmune Bio over Windtree Therapeutics.
Insider and Institutional Ownership
Institutional investors hold 29.3% of Windtree Therapeutics, while INmune Bio has 12.7%. Insiders hold 0.5% of Windtree and 35.2% of INmune Bio. Higher institutional ownership often suggests confidence in a company’s growth potential.
Summary
INmune Bio outperforms Windtree Therapeutics in 9 out of 13 comparison factors.
About Windtree Therapeutics
Windtree Therapeutics develops therapies for acute cardiovascular diseases, focusing on drugs like istaroxime for heart failure and AEROSURF for respiratory issues in infants.
About INmune Bio
INmune Bio is a clinical-stage company targeting drug development for immune system regulation and treatment of various cancers and Alzheimer’s disease.
Receive News & Ratings for Windtree Therapeutics Daily – Enter your email below to get daily updates on Windtree Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
`
